Press Release Archive

 
06.02.2020 - Pfizer Establishes New Program to Support Continued Biotechnology Innovation
*/ /*-->*/ /*-->*/

Pfizer Breakthrough Growth Initiative will invest up to $500 million across a portfolio of clinical-stage biotechnology companies

 
05.29.2020 - Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc.

 
05.29.2020 - Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer

NEW YORK and TOKYO, May 29, 2020 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc.

 
05.22.2020 - Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc.

 
05.18.2020 - Pfizer Prices $4,000,000,000 Debt Offering
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of four tranches of notes:

 
05.15.2020 - Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD).

 
05.14.2020 - Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
*/ /*-->*/ /*-->*/

20-valent pneumococcal conjugate vaccine elicits consistent immune response across three different lots

 
05.13.2020 - Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day on Monday, September 14, 2020 at 9:00 a.m. EDT. Pfizer postponed its Investor Day, originally scheduled for March 31, 2020, due to health and safety concerns around the COVID-19 pandemic.

 
05.12.2020 - Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the RBC Capital Markets 2020 Global Healthcare Conference on Tuesday, May 19, 2020 at 11:30 a.m. EDT.

 
05.08.2020 - Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting
*/ /*-->*/ /*-->*/

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Friday, May 15, 2020 at 10:00 a.m. EDT. The purpose of the call is to review the DMD data presentation at the American Society of Gene and Cell Therapy (ASGCT) 2020 Annual Meeting.

 
05.04.2020 - New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
*/ /*-->*/ /*-->*/

A new study published in The Journal of Infectious Diseases showed high rates of GBS infection among the elderly, African Americans, and people with chronic conditions

 
04.30.2020 - Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

Phase2 vaccine candidate, VLA15, is being evaluated for adult and pediatric indications in North America and Europe.

 
04.29.2020 - BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany

MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTech’s Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. The trial is the first clinical trial of a COVID-19 vaccine candidate in Germany. Pfizer and BioNTech plan to initiate trials for BNT162 in the United States upon regulatory approval, which is expected shortly.

 
04.23.2020 - Pfizer Hosts Virtual-Only Annual Meeting of Shareholders
*/ /*-->*/ /*-->*/

Declares 38-Cent Second-Quarter 2020 Dividend

 
04.22.2020 - BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
  • First COVID-19-related clinical trial to start in Germany
  • Initial dose escalation phase to target dose range of 1µg to 100µg
  • Clinical supply from BioNTech’s GMP-certified mRNA production facilities in Europe
  • Four vaccine candidates to enter clinical development

MAINZ, Germany and NEW YORK

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.